Analyst Michael Yee of UBS maintained a Buy rating on Gilead Sciences, retaining the price target of $175.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Yee has given his Buy rating due to a combination of factors tied to Gilead’s advancing HIV long‑acting portfolio and its competitive positioning. He highlights that early clinical results for GS‑3242, designed for dosing every six months in combination with lenacapavir, show encouraging drug exposure profiles and meaningful antiviral activity in people living with HIV, supporting confidence in longer‑interval regimens.
He also notes that Gilead is already progressing this program into Phase II with dosing expected in the first half of the year, underscoring strategic execution and a lead over rivals. In contrast, competing long‑acting candidates from GSK appear earlier stage with less mature and more variable pharmacokinetic data, which reinforces Gilead’s perceived advantage in durability, regimen simplicity, and commercial potential in HIV, supporting his positive view on the stock.
Yee covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Eli Lilly & Co, and AbbVie. According to TipRanks, Yee has an average return of 0.6% and a 43.28% success rate on recommended stocks.
In another report released yesterday, TipRanks – xAI also reiterated a Buy rating on the stock with a $169.00 price target.